

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene at a concentration of greater than about 0.001% to less than about 20% in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer.

2-9. (Canceled)

10. (Previously presented) The pharmaceutical composition of Claim 1 wherein said pharmaceutical composition is for the treatment of cancer of the skin, the mouth and digestive tract, the urinary and reproductive tracts, the respiratory tract, the head and neck, and the endocrine and lymphoreticular systems.

11-35. (Canceled)

36. (Currently amended) An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, said halogenated xanthene present in a concentration of

greater than about 0.001% to less than about 20%, and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer.

37. (Currently amended) An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, said halogenated xanthene present in a concentration of about 10%, and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer.